Common use of Development Records Clause in Contracts

Development Records. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, complete and accurate books and records pertaining to Development of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement. Such books and records shall (i) be appropriate for patent and regulatory purposes, (ii) be in compliance with Applicable Law, (iii) properly reflect all work done and results achieved in the performance of its Development activities hereunder, (iv) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement and (v) be retained by Licensee for at least [* * *] years after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such books and records maintained pursuant to this Section 3.3.3; provided that AstraZeneca shall maintain such records and information disclosed therein in confidence accordance with Article 6.

Development Records. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, complete and accurate books and records pertaining to Development of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement. Such books and records shall (i) be appropriate for patent and regulatory purposes, (ii) be in compliance with Applicable Law, (iii) properly reflect all work done and results achieved in the performance of its Development activities hereunder, (iv) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement and (v) be retained by Licensee for at least [* * *] three (3) years after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such books and records maintained pursuant to this Section 3.3.33.2.3; provided that AstraZeneca shall maintain such records and information disclosed therein in confidence accordance with Article 6.

Development Records. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, complete and accurate books and records pertaining to Development of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement. Such books and records shall (i) be appropriate for patent and regulatory purposes, (ii) be in compliance with Applicable Law, (iii) properly reflect all work done and results achieved in the performance of its Development activities hereunder, (iv) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement and (v) be retained by Licensee for at least [* * ***] years ([***]) [***] after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such books and records maintained pursuant to this Section 3.3.3; provided that AstraZeneca shall maintain such records and information disclosed therein in confidence accordance with Article 6.

Development Records. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, complete and accurate books and records pertaining to Development development of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement. Such books and records shall (ia) be appropriate for patent and regulatory purposes, (iib) be in compliance with Applicable Law, (iiic) properly reflect all work done and results achieved in the performance of its Development development activities hereunder, (ivd) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement and (ve) be retained by Licensee for at least [* * *] three (3) years after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca MedImmune shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such books and records maintained pursuant to this Section 3.3.33.1.3 at its expense and to the extent necessary to demonstrate compliance with the terms of this Agreement; provided that AstraZeneca MedImmune shall maintain such records and information disclosed therein in confidence accordance with Article 6.

Development Records. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, complete and accurate books and records pertaining to Development of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement. Such books and records shall (i) be appropriate for patent and regulatory purposes, (ii) be in compliance with Applicable Law, (iii) properly reflect all work done and results achieved in the performance of its Development activities hereunder, (iv) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement and (v) be retained by Licensee for at least [* * **] years after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca Nabriva shall have the right, during normal business hours and upon reasonable [**] prior written notice, to inspect and copy all such books and records maintained pursuant to this Section 3.3.3Clause 3.1(e) (Development Records); provided that AstraZeneca Nabriva shall maintain such records and information disclosed therein in confidence accordance with Article 6to the extent set forth in Clause 7 (CONFIDENTIALITY AND NON-DISCLOSURE).

Development Records. 4.5.1 Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, maintain complete and accurate books and records pertaining relating to Development the development of the Licensed Compounds and the Licensed Products hereunder, in sufficient detail to verify compliance with its the obligations under this Agreement. Such books and records shall (ia) be appropriate for patent and regulatory purposes, (iib) be in compliance with Applicable Law, (iiic) properly reflect all work done and results achieved in the performance of its Development all development activities hereunder, (ivd) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement and (ve) be retained by Licensee for at least [* * *] three (3) years after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such the books and records maintained by the Licensee and its Affiliates including, for clarity, any books and records of development provided to Licensee by any Sublicensee pursuant to this Section 3.3.34.4; provided that AstraZeneca shall maintain such records and information disclosed therein in confidence in accordance with Article 67.

Development Records. Licensee shall, and shall cause its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, complete and accurate books and records pertaining to Development of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement. Such books and records shall (i) be appropriate for patent and regulatory purposes, (ii) be in compliance with Applicable Law, (iii) properly reflect all work done and results achieved in the performance of its Development activities hereunder, (iv) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement and (v) be retained by Licensee for at least [*** * *] years after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca ArQule shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such books and records maintained pursuant to this Section 3.3.3Clause 3.1(d) (Development Records); provided that AstraZeneca ArQule shall maintain such records and information disclosed therein in confidence in accordance with Article 6Clause 7 (CONFIDENTIALITY AND NON-DISCLOSURE).

Development Records. Licensee Midatech shall, and shall cause its Affiliates and its and their respective Sublicensees to, maintain, in good scientific manner, complete and accurate books and records pertaining to research and Development of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement. Such books and records shall (i) be appropriate for patent and regulatory purposes, (ii) be in compliance with Applicable Law, (iii) properly reflect all work done and results achieved in the performance of its research and Development activities hereunder, (iv) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement and (v) be retained by Licensee Midatech for at least [* * ***] years after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. AstraZeneca Novartis shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such books and records maintained pursuant to this Section 3.3.33.1.4 to verify compliance by Midatech with its obligations under this Agreement; provided that AstraZeneca Novartis shall maintain such records and information disclosed therein in confidence accordance with Article 6.